Selegiline is an oral prescription medication used to treat cognitive dysfunction and senility in older dogs. It can also be used to treat Cushing's disease when it is caused by a pituitary tumor. It's a generic alternative to Anipryl, and it's the only FDA-approved drug for canine senility. It comes in a capsule form, so you can easily hide it in a pill pocket and give it as a tasty treat or disguise it in your pal's favorite wet food. Customers may receive this drug under the names l-deprenyl, Anipryl, Eldepryl.
- Treats Canine Cushing's disease
- Treats age-related cognitive problems in older dogs
- for use in Dogs
How it works
Selegiline increases the concentration of a nervous system messenger chemical called dopamine. Higher levels of dopamine improve many cognitive processes. Treating Cushing's Disease has traditionally been centered on suppressing the adrenal glands production and release of cortisone. However, this approach has a high potential for side effects. Selegiline has allowed for a new approach by suppressing the pituitary gland directly.
Selegiline hydrochloride capsules, USP are indicated as an adjunct in the management of Parkinsonian patients being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy. There is no evidence from controlled studies that selegiline has any beneficial effect in the absence of concurrent levodopa therapy.
Evidence supporting this claim was obtained in randomized controlled clinical investigations that compared the effects of added selegiline or placebo in patients receiving levodopa/carbidopa.
Selegiline was significantly superior to placebo on all three principal outcome measures employed: change from baseline in daily levodopa/carbidopa dose, the amount of off time, and patient self-rating of treatment success. Beneficial effects were also observed on other measures of treatment success (e.g., measures of reduced end of dose akinesia, decreased tremor and sialorrhea, improved speech and dressing ability and improved overall disability as assessed by walking and comparison to previous state).